文献速递中枢神经肿瘤放疗放疗物理与技术

新诊断幕上胶质母细胞瘤5次立体定向放射外科联合替莫唑胺的1/2期试验:健康相关生活质量结果

Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-02-07

该前瞻性剂量递增试验评估新诊断胶质母细胞瘤患者接受5次立体定向放射外科(25-40 Gy/5次)联合同步及辅助替莫唑胺治疗期间的健康相关生活质量。30例患者完成139份问卷,中位随访10.4个月,12个月时评估依从性76%。沟通障碍随时间显著恶化(每月下降1.7分,P=.008),其余8个主要HRQOL量表无显著变化,疾病进展与沟通障碍恶化相关。

要点

  • 5次立体定向放射外科联合替莫唑胺治疗期间整体HRQOL保持稳定
  • 沟通障碍随时间显著恶化,每月下降1.7分(P=.008)
  • 疾病进展后沟通障碍平均每月恶化13.9分,进展前为0.7分(P=.01)

核心结论

  • 在该5次剂量递增方案中,新诊断胶质母细胞瘤患者整体HRQOL保持稳定,且与30次放疗的历史对照相似。
  • 肿瘤复发与沟通障碍恶化相关,而放射性不良反应未与HRQOL下降相关。

研究设计与样本

  • 前瞻性剂量递增试验,5次立体定向放射外科(25-40 Gy/5次)联合同步及辅助替莫唑胺治疗新诊断胶质母细胞瘤。
  • 使用EORTC QLQ-C30、EORTC QLQ-BN20和MDASI-BT问卷,在基线和放疗后每次随访时评估HRQOL。
  • 30例患者共完成139份问卷,中位随访10.4个月(范围0.4-52个月),12个月时HRQOL评估依从性76%。

主要发现

  • 沟通障碍随时间显著恶化,每月下降1.7分(P=.008)。
  • 其他8个主要分析量表(包括整体生活质量)未检测到随时间显著变化。
  • 8例患者(27%)出现放射性不良反应,但未与任何主要HRQOL量表的统计学显著下降相关。
  • 疾病进展与沟通障碍相关,进展后平均每月恶化13.9分,进展前为0.7分(P=.01)。

临床怎么用

  • 对于新诊断胶质母细胞瘤患者,5次立体定向放射外科联合同步及辅助替莫唑胺治疗期间整体HRQOL可保持稳定。
  • 临床随访中应关注沟通障碍的变化,尤其是疾病进展后沟通障碍可能显著恶化。
  • 放射性不良反应的出现未与HRQOL下降相关,但需结合其他临床指标综合评估。

局限性

  • 该分析来自1/2期剂量递增试验,样本量30例,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide. METHODS: HRQOL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire core-30 (QLQ-C30) general, the EORTC quality of life questionnaire-brain cancer specific module (QLQ-BN20), and the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT). Questionnaires were completed at baseline and at every follow-up visit after completion of radiosurgery. Changes from baseline for 9 predefined HRQOL measures (global quality of life, physical functioning, social functioning, emotional functioning, motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty) were calculated at every time point. RESULTS: With a median follow-up time of 10.4 months (range, 0.4-52 months), 139 total HRQOL questionnaires were completed by the 30 patients on trial. Compliance with HRQOL assessment was 76% at 12 months. Communication deficit significantly worsened over time, with a decline of 1.7 points per month (P=.008). No significant changes over time were detected in the other 8 scales of our primary analysis, including global quality of life. Although 8 patients (27%) experienced adverse radiation effects (ARE) on this dose escalation trial, it was not associated with a statistically significant decline in any of the primary HRQOL scales. Disease progression was associated with communication deficit, with patients experiencing an average worsening of 13.9 points per month after progression compared with 0.7 points per month before progression (P=.01). CONCLUSION: On this 5-fraction dose escalation protocol for newly diagnosed GBM, overall HRQOL remained stable and appears similar to historical controls of 30 fractions of radiation therapy. Tumor recurrence was associated with worsening communication deficit, and ARE did not correlate with a decline in HRQOL.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pollom EL, Fujimoto D, Wynne J, et al. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586949. doi:10.1016/j.ijrobp.2017.01.242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。